This week, Penumbra announced the CE Mark and launch of three of its reperfusion catheters: RED™ 43, RED™ 72 with SENDit™ Technology, and RED™ 78 in Europe. These technologies expand Penumbra’s neurovascular offerings designed for acute ischemic stroke.
“I’m thoroughly impressed with the currently available RED aspiration catheters’ precision in navigating and removing clots,” said Dr. Levansri Makalanda, Clinical Lead for Neurointervention & Consultant Neuroradiologist at Barts Health NHS Trust, London. “I’m eagerly anticipating the RED 43, RED 72 SENDit and RED 78, which promise to enhance both the reach and efficiency of clot extraction.”
Optimizing Science-Based Aspiration Thrombectomy (S-BAT), RED 43, RED 72 with SENDit Technology, and RED 78 are engineered with the latest technology in trackability and aspiration to address a wide range of large vessel occlusions. The RED catheters feature REDglide™ technology, which enhances the trackability of the catheters as they navigate the challenging vasculature of the brain. Additionally, the RED catheters have a full-length PTFE liner designed to maintain their true lumen size under powerful vacuum further maximizing aspiration efficiency.
“Penumbra’s latest innovations offer physicians more options to provide care to their patients, regardless of the clot location,” said Joan Kristensen, head of the Europe, Middle East and Africa region for Penumbra, Inc. “Our focus is on pioneering technology and expanding access to these innovations with a goal of advancing the delivery of patient care in Europe and improving patient outcomes.”
In Europe, stroke is a leading cause of death and adult disability affecting approx. 1.1 million inhabitants of Europe every year and causing 440,000 deaths1. With the latest CE marked devices, Penumbra provides physicians with the most expansive aspiration thrombectomy stroke portfolio on the market.
Important Safety Information
Additional information about Penumbra’s products can be located on Penumbra’s website at
https://www.penumbrainc.com/eu/products/neuro-thrombectomy/. Prior to use, please refer to Instructions for Use for complete product indications, contraindications, warnings, precautions, potential adverse events and detailed instructions for use. Risk information can be found at peninc.info/risk.
1. Cardiovascular Disease Statistics 2023, Eurostat, https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Cardiovascular_diseases_statistics#Deaths_from_cardiovascular_diseases
Burden of Stroke in Europe, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7382540/#R1
Related Articles
-
Health
Lightning Bolt® 7 Case Study: Rapid Revascularization of Bilateral Renal Artery Occlusion with Computer Assisted Vacuum Thrombectomy (CAVT™)
-
Health
Latest Findings from Penumbra’s STRIKE-PE Study to be Presented at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Conference
-
Health
Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism
-
Health
Recent Data Show Positive Outcomes of Penumbra’s BENCHMARK™ BMX®81 System for Radial Access during Neurovascular Interventions